O1-3-4STUDY OF ANTIEMETIC EFFECTIVE USE IN ACUTE MYELOID LEUKEMIA TREATMENT

Abstract Chemotheraphy-Induced Nausea and Vomiting in cancer (CINV) is a factor which significantly reduces the quality of life (QOL) of patients by physical pain and emotional distress. For the purpose of making appropriate supportive care, “antiemetics proper use guidelines” was created in 2010.It has become possible to use granisetron and aprepitant, palonosetron from 2010 in Japan. In recent years, studies of antiemetics has been studied, but studies on the chemotherapy of hematopoietic malignancies still low. We thought in the chemotherapy of hematopoietic malignancies, and you want to consider the supportive care more effective. We have compared the effect of palonosetron and granisetron in consolidation therapy and remission induction of Acute Myeloid Leukemia. The incidence of nausea Grade 2 or more of acute, 24/47 cases of granisetron group (51%), 12/40 cases of palonosetron group (30%) P = 0.053. The incidence of nausea Grade 2 or more of Delayed 15/47 cases of granisetron group (32%), 7/40 cases of palonosetron group (30%) P = 0.144, As explained above and tended to the incidence of nausea Grade 2 or more of palonosetron group is small. However, both showed no significant difference. Comparing the price of each formulation, granisetron 3mg pack is 2874 yen, palonosetron 0.75mg is 14,522 yen. Granisetron be cheaper as unit price, but palonosetron be cheaper in the administered regimen consecutive days for one week before and after. Therefore, for the use of antiemetics in the treatment of acute myeloid leukemia, resulted palonosetron group is superior in cost-effective.